Enhanced glucosuria by sotagliflozin was associated with a nonsignificant trend for lower blood glucose levels (Figure 2m), and a 30% increase in plasma levels of GLP1 versus vehicle‐treated STN‐AngII (Figure 2n). This evidence concerns the gene GCG and Glycosuria.